<?xml version="1.0" encoding="UTF-8"?>
<p id="p0005">Acyclovir enabled the first systemic antiviral therapy, and many antiviral agents have subsequently been developed. Acyclovir targets herpes simplex virus and varicella-zoster infection, and individual antiviral agents target one viral infection caused by one virus or two viruses of the same family (
 <xref rid="bb0145" ref-type="bibr">Elion, 1982</xref>; 
 <xref rid="bb0515" ref-type="bibr">Shiraki, 2017</xref>, 
 <xref rid="bb0520" ref-type="bibr">Shiraki, 2018</xref>). Among antiviral agents, one of the unique features of favipiravir (T-705) is its broad spectrum activity toward RNA viruses, including influenza virus, rhinovirus, and respiratory syncytial virus, but not DNA viruses, as shown in 
 <xref rid="f0005" ref-type="fig">Fig. 1</xref> (
 <xref rid="bb0170" ref-type="bibr">Furuta et al., 2002</xref>; 
 <xref rid="bb0175" ref-type="bibr">Furuta et al., 2005</xref>; 
 <xref rid="bb0180" ref-type="bibr">Furuta et al., 2009</xref>). Favipiravir shows better efficacy in treating influenza infections than oseltamivir (Tamiflu) (
 <xref rid="bb0560" ref-type="bibr">Takahashi et al., 2003</xref>; 
 <xref rid="bb0580" ref-type="bibr">Tanaka et al., 2017</xref>), and its efficacy in treating pathogenic avian influenza A(H5N1) and oseltamivir-resistant viruses has been confirmed in animals (
 <xref rid="bb0300" ref-type="bibr">Kiso et al., 2010</xref>; 
 <xref rid="bb0535" ref-type="bibr">Sidwell et al., 2007</xref>).
</p>
